Knowledge Base
Evidence-based reference articles covering every aspect of retatrutide — from its novel triple-agonist mechanism to clinical trial outcomes, safety data, and development milestones. Each article is sourced from peer-reviewed research and regularly updated as new data emerges.
Essential Reading
Retatrutide (Reta) Week by Week: Results Timeline, Week 1 to 80
Reta week 2, week 4, week 6, 12 weeks in: what trial data show at each point, from 1% in week 1 to 24.2% at 48 weeks and 28.3% at 80 weeks (12 mg, investigational).
How Long Has Retatrutide Been Around? History Since 2016
Retatrutide (reta) has been around since about 2016 as a Lilly lab compound, first dosed in humans in 2019, with Phase 2 results in 2023 and five Phase 3 readouts in 2025-26.
Weight Loss Outcomes with Retatrutide: Clinical Trial Results and Analysis
A detailed analysis of weight reduction results from retatrutide clinical trials, including dose-response relationships, body composition changes, and contextual comparisons with other metabolic therapies.
Safety Profile of Retatrutide: Comprehensive Overview from Clinical Data
A thorough review of retatrutide's safety profile based on Phase 1, Phase 2, and Phase 3 TRIUMPH-4 clinical trial data, covering gastrointestinal adverse events, dysesthesia, laboratory findings, cardiovascular signals, hepatic effects, and outstanding safety questions.
Mechanism of Action: How Retatrutide's Triple Receptor Agonism Works
A deep dive into retatrutide's triple GIP/GLP-1/glucagon receptor agonism, explaining how each receptor pathway contributes to the molecule's metabolic effects and why synergistic triple agonism exceeds single- or dual-target approaches.
All Articles
Is Retatrutide Safe? What Clinical Data Shows
Retatrutide safety data from Phase 2 and Phase 3 trials: adverse events, dysesthesia, discontinuation rates, and what remains unknown.
Peptide Quality Verification: COAs, Purity, and Red Flags
How to verify peptide quality using COA certificates, purity testing, and independent analysis. Learn what separates verified products from the rest.
Research Peptides vs Pharmaceutical Grade
The real difference between research peptides and pharmaceutical-grade products: GMP manufacturing, quality controls, and what it means for safety.
Retatrutide and Heart Health: Cardiovascular Data
Retatrutide cardiovascular data: blood pressure, cholesterol, triglycerides, and lipid improvements from clinical trials. No outcomes data yet.
Retatrutide and Kidney Disease: CKD Research
Retatrutide kidney data: UACR reduction, eGFR changes, and the TRANSCEND-CKD trial design. Early evidence in chronic kidney disease.
Retatrutide and Osteoarthritis: TRIUMPH-4 Results
TRIUMPH-4 Phase 3 data: retatrutide achieved 28.7% weight loss and 75.8% knee pain reduction in adults with obesity and osteoarthritis.
Retatrutide, PCOS, and Fertility: Women's Health
Retatrutide and PCOS, fertility, pregnancy, and birth control: what GLP-1 class data suggest and why no retatrutide-specific evidence exists.
Retatrutide for Type 2 Diabetes: TRANSCEND Trial Data
Phase 3 TRANSCEND-T2D-1, published in The Lancet (June 2026), shows retatrutide achieved HbA1c reduction up to -1.94 points and 15.3% weight loss at 40 weeks in type 2 diabetes. Full peer-reviewed trial data and analysis.
Retatrutide and Alcohol: What the Evidence Shows
Review of evidence on retatrutide and alcohol interactions, GLP-1 effects on drinking behavior, and safety concerns for combining alcohol with GLP-1 agonists.
Retatrutide and Bodybuilding: Body Composition Data
Evidence-based review of retatrutide body composition data including fat loss, lean mass, and relevance to bodybuilding. DXA scan results from Phase 2.
Retatrutide Injection Guide: How It's Administered
How retatrutide is administered in clinical trials: injection sites, technique, pen device, needle gauge, storage, and dose escalation protocol.
How to Get Retatrutide: Clinical Trials, Access, and Availability
Not approved as of September 2026. The two legitimate routes: clinical trials and Lilly's narrow expanded access program. BLA planned Q1 2027; decision 2027-28.
Retatrutide Cost and Pricing: What to Expect When It's Approved
No price set for retatrutide (not yet FDA-approved). Based on tirzepatide pricing, analyst projections, and the biologic lawsuit, here's what it may cost.
Is Retatrutide FDA Approved? Status and Release Date (2026)
Not approved as of September 2026. All five pivotal trials reported; Eli Lilly plans a BLA in Q1 2027, so the earliest FDA decision is late 2027, base case 2028.
Retatrutide Side Effects: Complete Guide to Clinical Trial Safety Data
Retatrutide side effects from Phase 2 and Phase 3 trials: GI events by dose, discontinuation rates, the TRIUMPH-4 dysesthesia signal, and GLP-1 comparisons.
Retatrutide Receptor Activity: GLP-1, GIP, and Glucagon Pathways
An in-depth analysis of retatrutide's activity at the GLP-1, GIP, and glucagon receptors, including relative potency, selectivity, and why triple agonism produces synergistic metabolic effects that exceed dual-agonist approaches like tirzepatide.
Retatrutide Half-Life and Dosing: Pharmacokinetic Profile Explained
A comprehensive explanation of retatrutide's pharmacokinetic profile, including its approximately 6-day terminal half-life, subcutaneous absorption characteristics, steady-state kinetics, and how these properties compare with semaglutide and tirzepatide.
Retatrutide Development Timeline: From Discovery to Phase 3
Timeline of retatrutide from discovery through Phase 3, including TRIUMPH-4 results (-28.7% weight loss), dose escalation, and upcoming 2026 readouts.
Liver Fat Reduction with Retatrutide: MASLD/NAFLD Implications
An analysis of retatrutide's effects on hepatic steatosis, including clinical trial data on liver fat reduction, the glucagon-mediated mechanism behind these effects, and implications for MASLD/NAFLD treatment.
Metabolic Effects of Retatrutide: Glycemic, Lipid, Hepatic, and Cardiovascular Outcomes
An examination of retatrutide's broad metabolic effects beyond weight loss, including glycemic control, lipid improvements, blood pressure reduction, liver fat changes, and implications for metabolic syndrome.
What Is Retatrutide? A Comprehensive Overview of LY3437943
An in-depth introduction to retatrutide (LY3437943), the first-in-class triple GIP/GLP-1/glucagon receptor agonist in development by Eli Lilly for obesity and type 2 diabetes.
Pharmacokinetics of Retatrutide: Absorption, Distribution, Metabolism, and Excretion
A review of retatrutide's pharmacokinetic profile, including its approximately 6-day half-life, subcutaneous bioavailability, albumin binding, and the PK basis for once-weekly dosing.
Pharmacology of Retatrutide: Drug Class, Receptor Binding, and Signal Transduction
A detailed examination of retatrutide's pharmacological profile, including receptor binding affinities, signal transduction pathways, dose-response relationships, and preclinical pharmacology data.